IL264391A - Preparations - Google Patents

Preparations

Info

Publication number
IL264391A
IL264391A IL264391A IL26439119A IL264391A IL 264391 A IL264391 A IL 264391A IL 264391 A IL264391 A IL 264391A IL 26439119 A IL26439119 A IL 26439119A IL 264391 A IL264391 A IL 264391A
Authority
IL
Israel
Prior art keywords
polyoxylglyceride
compositions
carboxymethyl cellulose
polyalkylene glycol
cholesterol sulfate
Prior art date
Application number
IL264391A
Other languages
English (en)
Hebrew (he)
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of IL264391A publication Critical patent/IL264391A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL264391A 2016-08-02 2019-01-22 Preparations IL264391A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370200P 2016-08-02 2016-08-02
US201762470834P 2017-03-13 2017-03-13
PCT/US2017/044934 WO2018026837A1 (en) 2016-08-02 2017-08-01 Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride

Publications (1)

Publication Number Publication Date
IL264391A true IL264391A (en) 2019-02-28

Family

ID=61074228

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264391A IL264391A (en) 2016-08-02 2019-01-22 Preparations

Country Status (12)

Country Link
US (2) US20200222430A1 (enExample)
EP (1) EP3493810A4 (enExample)
JP (2) JP7048576B2 (enExample)
KR (1) KR102462275B1 (enExample)
CN (1) CN109922811B (enExample)
AU (1) AU2017305305A1 (enExample)
BR (1) BR112019001225A2 (enExample)
CA (1) CA3031215A1 (enExample)
IL (1) IL264391A (enExample)
MX (1) MX391441B (enExample)
TW (1) TW201818946A (enExample)
WO (1) WO2018026837A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
EA201990684A1 (ru) 2013-12-24 2020-12-30 Вирджиния Коммонвелт Юниверсити Способы применения оксигенированных холестеролсульфатов (ocs)
IL298681A (en) 2016-08-02 2023-01-01 Univ Virginia Commonwealth Preparations
WO2021005399A1 (en) * 2019-07-08 2021-01-14 The University Of Hong Kong Compositions and methods for clearing tissue
JP7830313B2 (ja) * 2019-09-30 2026-03-16 デュレクト コーポレーション アルコール性肝炎の処置
CN115103591B (zh) * 2019-12-27 2026-06-19 度勒科特公司 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法
CA3170320A1 (en) * 2020-02-11 2021-08-19 Durect Corporation Treatment of infectious diseases
ES3004508T3 (en) * 2020-04-15 2025-03-12 Gruenenthal Gmbh Resiniferatoxin compositions
CN115803061A (zh) * 2020-05-22 2023-03-14 度勒科特公司 非酒精性脂肪性肝炎(nash)的治疗
JP2023527153A (ja) * 2020-05-22 2023-06-27 デュレクト コーポレーション 非アルコール性脂肪性肝炎(nash)の処置
CA3187310A1 (en) 2020-06-26 2021-12-30 Durect Corporation Use of oxygenated cholesterol sulfates for treating autoimmune conditions
US20240425545A1 (en) * 2021-06-25 2024-12-26 Durect Corporation 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same
CN114306350B (zh) * 2022-01-13 2023-01-24 四川大学华西医院 胆固醇硫酸盐在制备预防脓毒症的药物中的用途
CN114646702B (zh) * 2022-03-03 2023-01-06 四川大学华西医院 胆固醇硫酸酯检测试剂在制备脓毒症辅助诊断、治疗效果监测和预后评估试剂盒中的用途
WO2024136884A1 (en) * 2022-12-23 2024-06-27 Durect Corporation Salts including crystalline salts of 25-hydroxy-cholest-5-en-3-sulfate and methods for preparing same
CN121695995A (zh) * 2024-09-18 2026-03-20 深圳翰宇药业股份有限公司 一种多肽药物的粉碎方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
IS6633A (is) * 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US20090149434A1 (en) * 2005-09-29 2009-06-11 Joseph Podolski Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
EP1983972A4 (en) 2006-02-13 2012-01-25 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
US8003795B2 (en) 2007-06-22 2011-08-23 Cvi Pharmaceuticals Limited Compounds and compositions for reducing lipid levels
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
CN104220450B (zh) * 2012-04-12 2016-07-06 弗吉尼亚联邦大学 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS)
EP2842547A1 (en) * 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Improved fenofibrate compositions
EA201990684A1 (ru) * 2013-12-24 2020-12-30 Вирджиния Коммонвелт Юниверсити Способы применения оксигенированных холестеролсульфатов (ocs)
WO2016005994A2 (en) * 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires
BR112017007025A2 (pt) * 2014-10-10 2017-12-12 Univ Virginia Commonwealth sulfatos de colesterol oxigenados para terapia de distúrbios causados por pelo menos um de atividade de leptina atenuada e um distúrbio de armazenamento de lipídio

Also Published As

Publication number Publication date
MX391441B (es) 2025-03-21
WO2018026837A1 (en) 2018-02-08
JP2019526542A (ja) 2019-09-19
US20200222430A1 (en) 2020-07-16
EP3493810A4 (en) 2020-04-08
MX2019001327A (es) 2019-07-08
KR102462275B1 (ko) 2022-11-01
AU2017305305A1 (en) 2019-02-21
US20220175798A1 (en) 2022-06-09
CA3031215A1 (en) 2018-02-08
CN109922811A (zh) 2019-06-21
TW201818946A (zh) 2018-06-01
CN109922811B (zh) 2023-09-19
JP2022084831A (ja) 2022-06-07
KR20190032529A (ko) 2019-03-27
BR112019001225A2 (pt) 2019-04-30
JP7048576B2 (ja) 2022-04-05
EP3493810A1 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
IL286493A (en) Triterpene saponin analogs, methods for their production, preparations containing them and their uses
PL3628691T3 (pl) Amfifilowe pochodne polisacharydów i zawierające je kompozycje
IL286391A (en) Penfluramine preparations and methods for their preparation
IL271275B1 (en) Preparations containing croons and their uses
EP3493810A4 (en) COMPOSITIONS WITH OXYGENOUS CHOLESTERINSULFATE AND AT LEAST POLYALKYLENE GLYCOL, CARBOXYMETHYLCELLULOSE OR POLYOXYL GLYCERIDE
EP3397709A4 (en) OLIGOESTERS AND COMPOSITIONS THEREOF
PL3328317T3 (pl) Wciąganie lub/i podtrzymywanie tkanki otaczającej cewkę moczową
SG11201707876YA (en) Microalgal compositions and uses thereof
EP3125914A4 (en) Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof
ZA201903928B (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
EP3257922A4 (en) Lubricant composition, use thereof and aliphatic ether compound
IL253705B (en) Converted triazoles, preparations containing them and their uses
IL250607B (en) Aripiprazole prodrug compositions and uses thereof
GB201502002D0 (en) Uses and compositions
HUE065760T2 (hu) Csökkentett gluténtartalmú gabonaszemek és azok készítményei
IL266840A (en) History of tyrosine and preparations containing them
PL3247691T3 (pl) Kompozycje zapachowe i smakowe zawierające dioctan glikolu neopentylowego
GB2543062B (en) Improved high-pressure axial-flow fan blade and contra-rotating axial-flow fan having the same
IL273967A (en) Aqueous preparations containing bilastin and methotrexate
GB201501991D0 (en) Uses and compositions
PL3510102T3 (pl) Kompozycje tereftalanu polialkilenu
PL3544615T3 (pl) Kompozycja doustna zawierająca beta-escynę i sok z aronii do obniżania toksyczności aldehydu octowego
HK40009771A (zh) 包含氧化胆固醇硫酸酯以及聚亚烷基二醇、羧甲基纤维素和聚氧乙烯甘油酯中至少一种的成分
GB201511886D0 (en) Uses and compositions
GB201913956D0 (en) Inhalable cannabinoid compositions and uses